Zhengbin Bing Yao, Ph.D, is a distinguished leader in the biotechnology industry, currently serving as the Chief Executive Officer and President of ARRIVENT BIOPHARMA INC. Dr. Yao's professional journey is marked by his profound expertise in oncology drug development and strategic leadership. Before joining ARRIVENT, he held pivotal roles at major pharmaceutical companies, including Bristol-Myers Squibb and Novartis, where he contributed significantly to the development and commercialization of innovative cancer therapies. At ARRIVENT BIOPHARMA INC, Dr. Yao has been instrumental in steering the company towards its mission of accelerating the development of breakthrough cancer treatments. Under his leadership, ARRIVENT has successfully advanced its pipeline, focusing on novel therapies that address unmet medical needs in oncology. His strategic vision and commitment to scientific excellence have not only fostered a culture of innovation within the company but also strengthened its position in the competitive biopharma landscape. Dr. Yao's achievements extend beyond his corporate roles; he is also recognized for his contributions to the scientific community through numerous publications and presentations at international conferences. His dedication to advancing cancer research and his ability to forge strategic partnerships have been key to ARRIVENT's growth and success. As CEO and President, Dr. Yao continues to drive the company forward, leveraging his extensive experience and passion for improving patient outcomes in the fight against cancer.